Purpose. To study the effect of spectacle lenses Stellest™ use on refraction, axial length (AL) and accommodation parameters in children with myopia. Methods. The study included 107 children (214 eyes) aged 7 to 16 years (10.0±1.7 years) with progressive myopia from –0.5 to –7.0 D in spherical equivalent of refraction (–2.6±1.6 diopters), astigmatism from –0.75 to –4.0 D was present in 28 % of cases. Spectacle lenses Stellest™ have always been prescribed for continuous wear (at least 12 hours per day). The dynamics was studied after 6 months (in 38 children, 76 eyes) and 12 months (in 25 children, 50 eyes) from the start of wearing Stellest™. Results. The average change in cycloplegic refraction was 0.06±0.01 D. In the first 6 months, stabilization of refraction was achieved in 72 % (55 eyes), and in 22 % (17 eyes) a weakening of cycloplegic refraction (+0.5 D) was detected. During 12 months, stable cycloplegic refraction was detected in 56 % of cases (28 eyes), and its weakening (by +0.5 diopters) or strengthening (up to –0.75 diopters) was equally frequent – in 22 % (11 eyes). Myopia progression annual gradient during wearing Stellest™ was 0.1 D (p<0.05). The stock of relative accommodation increased significantly to -4.0 diopters (р<0.05). The initial axial length in the group as a whole was 24.5±0.1 mm. For the first 6 months, growth of the AL did not exceed 0.02 mm, for 12 months – 0.1 mm. Conclusions. Spectacle lenses Stellest™ can be recommended as a reliable means of optical correction, helping to slow down the rate of progression and stabilize myopia. Stabilization of myopia within 12 months was achieved in 78 % of patients. Key words: myopia progression; myopia in children; peripheral myopic defocus; Stellest glasses.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.